Results 11 to 20 of about 16,526 (218)

FDA-Approved Antibacterials and Echinocandins

open access: yesAntibiotics
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA).
Othman Al Musaimi
doaj   +4 more sources

Fungal echinocandin resistance [PDF]

open access: yesF1000 Biology Reports, 2010
Echinocandins are the most recent introduction to the antifungal armamentarium and target the synthesis of β-(1,3)-glucan, the major structural polysaccharide of the fungal cell wall. Mechanisms have been identified that reduce the efficacy of the echinocandins: mutations of the Fks subunit of the target enzyme complex or a compensatory increase in the
Walker, Louise A.   +2 more
openaire   +4 more sources

Post-Prescription Audit Plus Beta-D-Glucan Assessment Decrease Echinocandin Use in People with Suspected Invasive Candidiasis

open access: yesMedicina, 2021
Background and Objectives: Overtreatment with antifungal drugs is often observed. Antifungal stewardship (AFS) focuses on optimizing the treatment for invasive fungal diseases.
Rita Murri   +11 more
doaj   +1 more source

Set of Classical PCRs for Detection of Mutations in Candida glabrata FKS Genes Linked with Echinocandin Resistance [PDF]

open access: yes, 2014
Clinical echinocandin resistance among Candida glabrata strains is increasing, especially in the United States. Antifungal susceptibility testing is considered mandatory to guide therapeutic decisions.
Afeltra, Javier   +7 more
core   +2 more sources

Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis

open access: yesAntibiotics, 2022
Although combination therapy using trimethoprim–sulfamethoxazole (TMP–SMX) plus echinocandins has been reported to reduce the mortality of patients with pneumocystis pneumonia (PCP), it remains unclear whether it is more effective than TMP–SMX ...
Hideo Kato   +8 more
doaj   +1 more source

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

open access: yesMicroorganisms, 2021
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates ...
Renátó Kovács   +7 more
doaj   +1 more source

Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies [PDF]

open access: yes, 2015
Date of Acceptance: 23/07/2015 We thank Gillian Milne for help with electron microscopy, Sophie M. Schäfer for pilot experiments, and Emilia Mellado for strains. All authors acknowledge financial support of Gilead Sciences through Ph.D.
Gow, Neil A R   +3 more
core   +1 more source

Quantitative Analysis of Candida Cell Wall Components by Flow Cytometrywith Triple-Fluorescence Staining [PDF]

open access: yes, 2017
This work was supported by the European Commission within the FP7 Framework Programme [Fungitect-Grant No 602125]. We also thank Thomas Sauer, Vienna Biocenter Campus (VBC), Austria, for technical support at the FACS facility of the MFPL, Karl Kuchler ...
Gow, N   +5 more
core   +1 more source

Pan-Echinocandin Resistant C. parapsilosis Harboring an F652S Fks1 Alteration in a Patient with Prolonged Echinocandin Therapy

open access: yesJournal of Fungi, 2022
The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days of micafungin followed ...
Maria Siopi   +12 more
doaj   +1 more source

Micafungin: A New Echinocandin [PDF]

open access: yesClinical Infectious Diseases, 2006
Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
P H, Chandrasekar, J D, Sobel
openaire   +2 more sources

Home - About - Disclaimer - Privacy